A recent meta-analysis explored the impact of BRCA1 and BRCA2 mutations on survival of ovarian and breast cancer, and claimed that these mutations should be considered when designing appropriate treatment strategies [43]. The gene discussed is BRCA2; the disease is breast carcinoma.